Skip to content

Endocrine & reproductive

Organ-specific peptides for the glands.

  • Route3 of 5 to organ-specific bioregulation
  • Options15

Is this pathway actually your problem?

This is the class where a before-and-after matters most, because the whole proposition is unverified. If a testicular bioregulator does what the program claims, LH and testosterone are where it would show.

What engages this pathway

Ordered by how directly each one acts on the mechanism, never by how much trial evidence exists. Each opens its full breakdown.

Code CAMERON

Most options here use this code. Each Shop link copies its own as the store opens.

Show 7 more options

The free peptide field guide

The 12 compounds people ask about most: how each one works, what the research shows, the markers that say whether it is doing anything, and what most people get wrong.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

How it works, in full

How this pathway works

The mechanism in full

Organ-specific peptides for the glands. Note how this maps onto the hormonal goals — the bioregulator argument is upstream of hormone replacement rather than an alternative to it.

What each option’s mechanism predicts here

15 predictions, in full
Testoluten

Testicular bioregulator, proposed to support endogenous Leydig-cell function. The theory would place it upstream of everything in the testosterone goal; there is no human trial to say whether it does anything.

Testagen

A synthetic testicular tripeptide from the same program.

Ovagen

Ovarian and hepatic bioregulator, proposed in the program to support follicular function. No independent human data exists for either target.

Zhenoluten

The A-series ovarian peptide, positioned in the program as the female counterpart to Testoluten and overlapping Ovagen's target. Proposed to act on ovarian tissue as it ages rather than to supply estrogen, which would place it upstream of hormone replacement. No independent human data, in common with the rest of the series.

Prostamax

Prostate bioregulator. Prostatilen, a related prostate peptide, has actual Russian clinical use in chronic prostatitis — the closest this class gets to established practice.

Libidon

The prostate peptide of the A-series, the same target as Prostamax above. Prostate is the one corner of this class with real clinical use behind a relative — Prostatilen in chronic prostatitis — which is still not evidence for this one. Run a PSA before reasoning about any of it.

Endoluten

Pineal-endocrine bioregulator, positioned in the program as the master endocrine peptide.

Glandokort

The adrenal peptide, and the most-wanted and least-verifiable target in the series — everybody wants an adrenal answer and nobody outside the program has looked. Proposed to act on adrenal tissue rather than to supply cortisol, which is not a treatment for adrenal insufficiency.

Suprefort

Pancreatic bioregulator, proposed for glucose regulation. If it works at all it belongs in the metabolic goal — which is exactly the sort of claim that needs a trial.

Bonothyrk

The parathyroid peptide, aimed at the gland that governs calcium handling. If tissue specificity held anywhere in the endocrine set this would be a good place to look for a measurable answer, since PTH and calcium are cheap to track — and nobody has published that measurement.

Pancragen

The synthetic pancreatic tetrapeptide distilled from Suprefort's active fragment — the reductionist version of the same proposed signal.

Tiramin

The thyroid CYTAMIN, and the entry where the class premise runs out of evidence: four organotypic-culture papers carry the tissue-specificity claim across nine tissues and none of them used thyroid. The thyroid is a closed feedback loop, so a real effect shows on TSH within about six weeks — which makes this the easiest organ on the shelf to demonstrate and nobody has. The safety question for an unassayed animal thyroid preparation is hormone content: when a comparable glandular category was tested by chromatography, 9 of 10 products contained detectable T3.

Prostalamin

The prostate CYTAMIN. This is the cheapest item in the class to falsify and nobody has: PSA, the International Prostate Symptom Score, uroflow and post-void residual are all validated and none is expensive, and not one of the four has ever been reported for it. New urinary symptoms in a man over 50 are a reason for a workup rather than a 40-day course.

Thyreogen

The thyroid peptide. Note what it is not: a tissue-signal claim, not thyroid hormone, so even under the program's own theory a diagnosed hypothyroid patient is not the person it is aimed at.

Suprenamin

The adrenal CYTAMIN, and the one product in this line whose organ has no experiment behind it at all — the tissue-specificity claim has been tested in dishes on nine tissues and a search for peptide bioregulators and the adrenal cortex on 8 Sep 2026 returned zero. It is bought for a state that is not a recognized diagnosis. Morning cortisol, ACTH and DHEA-S would settle it in one draw, and the two Russian papers naming this class in humans, in servicemen and in athletes, report no cortisol measurement.

The deep read

What decides it, the order to test, what cannot move it

What actually decides this outcome, in order of size

Something is different about this page compared with every other bioregulator pathway, and it is the reason to read it carefully: every claim made here has a blood test attached to it. Ranked by how much of the outcome each one owns:

  1. That these claims are falsifiable, and have not been falsified. A testicular peptide proposing Leydig support predicts a measurable change in testosterone and gonadotropins. An ovarian one predicts a change in a follicular marker. A pancreatic one predicts a change in glycemic handling. A prostate one predicts a change in a prostate-specific antigen and a symptom score. Every one of those numbers is orderable today. Nobody outside the originating program has run any of those comparisons.
  2. Where the closest supporting result comes from, and it is a primate study. The tetrapeptide pancragen was examined for its impact on endocrine function in aging animals Goncharova 2014. That is the nearest thing on this page to an endocrine endpoint measured in a living organism, and it is not a human trial.
  3. What the mechanism claim actually is, because it is a transcriptional one. Peptide regulation of gene expression has a systematic review from within the program Khavinson 2021, structural motifs for peptide-DNA binding have been searched for systematically Kolchina 2019, and transport of ultrashort peptides through amino acid transporters has been modeled Khavinson 2023. A cell-level effect on the monocyte line has been reported with international co-authorship Avolio 2022, which is the broadest authorship any of this work has.
  4. Whether the reader is treating an axis that is already measurably abnormal, or one they assume is. A low testosterone needs a repeated morning sample and a gonadotropin pair before anything is concluded Bhasin 2018. Buying a testicular peptide without that pair is the same mistake the whole testosterone-booster category makes, and that category has been systematically reviewed and found largely unsupported Morgado 2023.
  5. The peptides, last, and the only human outcome ever claimed for the series is survival. Pineal and thymic peptide preparations were reported to prolong human life in a long-running follow-up Khavinson 2003, with earlier animal work on vilon Khavinson 2000. That is the largest claim on this site and it rests on a body of work that an outside review of the broader class treats cautiously Alsulaimani 2021.

The order to run these in, and what has to be true first

Measure the axis before signaling to it. This page is the one place on the site where a reader can run the experiment the literature has not run, and doing it in the wrong order wastes the only informative thing about the purchase.

  1. Decide which axis you are buying for, and take its baseline first. One requisition per axis, morning, and a repeat draw on a separate day for anything that is going to drive a decision Bhasin 2018. Without a baseline there is no experiment, only a subscription.
  2. Testoluten and Testagen predict a change in LH & FSH and Total Testosterone with SHBG (Sex Hormone-Binding Globulin). If the proposal is Leydig-cell support, the honest signature is testosterone rising while luteinizing hormone stays flat or falls, because a gonadal effect relieves the feedback. Testosterone rising with LH rising means something acted above the testis, which is a different claim from the one on the label.
  3. Ovagen predicts a change in Anti-Müllerian Hormone (AMH) with Progesterone timed to the luteal phase. Anti-Mullerian hormone reflects the antral follicle pool and is comparatively stable across the cycle, which makes it the one follicular marker a before-and-after comparison can use. There is no independent human data for this peptide on that endpoint or any other.
  4. Prostamax predicts a change in PSA (Total + Free + % Free) and in a symptom score, and the first of those has a safety meaning. Prostate-specific antigen is not only an efficacy read-out on this page; it is the number that must not be allowed to drift upward unexamined while somebody attributes their symptoms to a peptide. This is the single most important instruction on the page.
  5. Suprefort and Pancragen predict a change in Fasting Insulin, C-Peptide, Serum and HbA1c (Hemoglobin A1c). The animal endocrine work is the pancreatic one Goncharova 2014, and C-peptide is the analyte that separates endogenous insulin output from exogenous insulin. If a pancreatic peptide does anything, this is where it would show, and a 12-week HbA1c is the window.
  6. Endoluten is positioned as the master endocrine peptide and is the hardest to test. Melatonin is not on this site's marker list and the pineal claim has no ordinary assay, so the falsifiable proxies are IGF-1 (Insulin-like Growth Factor 1) and Prolactin, both of which are sleep-linked. That makes the honest version of this peptide's claim a circadian one, and it routes to Circadian & melatonergic rhythm for anybody whose actual complaint is sleep timing.
  7. Do not run two of these at once. Each targets a different axis with a different read-out and a different window, and running a testicular and a pancreatic peptide in the same 12 weeks makes both results uninterpretable. The whole value of this page is that it is testable.

What gets bought for this that cannot move it

The category fails on independent replication, and on this page it fails harder than on the organ page next door, because here the test exists. The evidence base is a single research program Khavinson 2021 Kolchina 2019 with an outside review of the broader class that is not enthusiastic Alsulaimani 2021. When a claim can be checked with a routine assay and has not been checked in thirty years, that absence is itself information.

Prostamax is the item here with a real potential for harm, and the harm is delay. A man attributing urinary symptoms to a peptide and not tracking PSA (Total + Free + % Free) is doing the one thing this page must tell him not to do. The peptide has no independent human evidence; the antigen has decades of it. Whatever else happens, the number gets watched.

The oral preparations are the half of this shelf whose equivalence claim is weakest. The transport argument is structural and computational Khavinson 2023, and the reported cellular effects are in culture Avolio 2022. Neither establishes that an orally administered tri- or tetrapeptide reaches an endocrine gland in a person at a concentration that does anything.

And if the axis is genuinely abnormal, this is the wrong page. A low testosterone with a low or normal LH belongs at Upstream stimulation — keeping the axis running, which has drugs with trials. Irregular cycles and androgen excess belong at PCOS — insulin, androgens & ovulation. A raised HbA1c belongs at AMPK activation & cellular fuel sensing and Glucose disposal, absorption & the post-meal curve. A rising PSA belongs with a urologist the same month.

How you would know it was working, on a real read-out and a real timescale

This page's prediction is the sharpest in the cohort because every claim on it is numeric. If a testicular peptide works as described, Total Testosterone rises while LH & FSH does not. If a pancreatic one works, C-Peptide, Serum and HbA1c (Hemoglobin A1c) move together. If nothing moves in 12 weeks on a correctly-timed pair of draws, the peptide did not do the thing it is sold to do, in you.

  • Total Testosterone with LH & FSH and SHBG (Sex Hormone-Binding Globulin), morning and fasted, at baseline and 8 weeks. Eight weeks because a gonadal effect has to work through Leydig steroidogenesis and then through pituitary feedback, and because a shorter window cannot separate a real change from the diurnal and day-to-day variability of the hormone Bhasin 2018.
  • Anti-Müllerian Hormone (AMH) at baseline and 3 months for the ovarian claim. Anti-Mullerian hormone reflects a follicle pool that turns over slowly, so a 3-month interval is the shortest one in which a change would mean anything, and a change inside the assay's own variability means nothing.
  • PSA (Total + Free + % Free) at baseline and 3 months for the prostate claim, and then regardless of the peptide. The interval is set by the antigen's half-life and by the fact that transient elevations from prostatitis, cycling and ejaculation settle over weeks. This is a safety read-out first and an efficacy read-out second.
  • Fasting Insulin with C-Peptide, Serum and HbA1c (Hemoglobin A1c) at baseline and 12 weeks for the pancreatic claim. C-peptide is co-secreted with insulin at one to one and is cleared more slowly, which makes it the better index of endogenous beta-cell output; the animal endocrine work is the closest supporting evidence Goncharova 2014.
  • IGF-1 (Insulin-like Growth Factor 1) with Prolactin at baseline and 12 weeks for the pineal claim. Both are sleep-linked and both are orderable, which makes them the only falsifiable proxies available for a peptide whose stated target has no routine assay.

What will fool you. Testosterone falls with a bad week and rises with a good one, so a single pair of draws around a stressful period will show whatever the period did. AMH differs between assay platforms enough that a laboratory change invalidates the comparison. PSA rises transiently after cycling, ejaculation or a urinary infection, so a raised value is repeated before it is acted on. And the strongest claim attached to this series is a survival claim from within the program itself Khavinson 2003, which is precisely the kind of endpoint no reader can verify on themselves in any timeframe Alsulaimani 2021.

Sources read for these sections

The markers that test it

6 markers

Retest timing, taken from each marker’s own page. When to retest: Total Testosterone, 6–8 weeks after any protocol change, every 3–6 months on TRT; Free Testosterone, with every total T retest — they must be interpreted together; LH & FSH, baseline before TRT, when investigating low T, when planning fertility; Estradiol, Sensitive (LC/MS-MS), 6–8 weeks after any TRT or AI change; Fasting Insulin, every 3–6 months, or 8–12 weeks after an intervention; HbA1c (Hemoglobin A1c), every 3 months (matches red cell lifespan).

Where each one should sit, from the same pages: Fasting Insulin, <8 µIU/mL; HbA1c (Hemoglobin A1c), <5.4%.

The other 4 routes to organ-specific bioregulation

Pick the pathway that matches where you are actually stuck

How to read the evidence labels

Nothing here is ranked by tier

Nothing here is ranked by evidence tier. A lot of what works in this space has never had the trial run, and sorting by trial count would bury exactly the compounds you came looking for. The tier is a label. The mechanism is the map.

Of the 15 options on this page, 15 (100%) on mechanism and lab or animal work.

Questions people ask

4 answered
What is the endocrine & reproductive pathway for organ-specific bioregulation?
Organ-specific peptides for the glands. Note how this maps onto the hormonal goals — the bioregulator argument is upstream of hormone replacement rather than an alternative to it.
What compounds and supplements work through endocrine & reproductive?
15 options are mapped to this pathway in the Vault, including Testoluten, Testagen, Ovagen, Zhenoluten. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 0 carry clinical validation and 15 are mechanistic predictions.
How do I know if endocrine & reproductive is actually my problem?
This is the class where a before-and-after matters most, because the whole proposition is unverified. If a testicular bioregulator does what the program claims, LH and testosterone are where it would show. The markers worth checking are Total Testosterone, Free Testosterone, LH & FSH, Estradiol, Sensitive (LC/MS-MS).
Are the 15 theoretical options for endocrine & reproductive worth considering?
Unproven is not the same as ineffective. Of the 15 options on this pathway, 0 have clinical validation and 15 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Inside Skool · $10/mo

The Organ-specific bioregulation Blueprint is in Skool

This pathway is one arm of The Organ-specific bioregulation Blueprint. The members’ version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.

  • Where each pathway sits in the sequence, and what runs first
  • What stacks with what, and what never overlaps
  • The markers that tell you to keep going or stop
Join Skool $10/moCancel anytime

5.0 (15 reviews)1,500+ members

Coach Cam's community on Skool: the public page, with the rating, members and price

Want it built around you?

The coaching app, shown with sample data

1-on-1 coaching

Cam and Coach Reece build training, nutrition, protocol and bloodwork around you. It starts with a free call.

from $150/mo

Apply for coaching

Ask Cam one question

Fifteen minutes on one topic, usually enough to settle which option is yours.

$75 per call

Book 15 minutes

The blueprint this pathway sits inside

Educational and research reference only — not medical advice, and not a recommendation for human use. Mechanistic predictions are exactly that: what the biology suggests should happen, which is not the same as what has been shown to happen. Some links are affiliate links. Medical disclaimer and affiliate disclosure